Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

NICE technology appraisals [TA263] Published date:

NICE does not recommend bevacizumab in combination with capecitabine as first-line treatment for metastatic breast cancer when other chemotherapy (including drugs known as taxanes or anthracyclines) is not appropriate, or taxanes or anthracyclines have been given in the past 12 months.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. It was not clear from the evidence whether using bevacizumab with capecitabine provides enough benefit to patients to justify its high cost, and it did not qualify for special consideration, so NICE did not recommend it.

Get involved